CELC Celcuity Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1603454 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-57.3%
TTM EPS YoY-28.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-1,192.9%
ROA-42.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets110.2%
Debt / equity—
Current ratio14.62x
Interest coverage-11.94x
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-7.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $145.00M | $104.20M |
| SG&A expense | $27.20M | $9.06M |
| Operating income | -$172.19M | -$113.27M |
| Interest expense | $17.15M | $10.28M |
| Pretax income | -$177.04M | -$111.78M |
| Net income | -$177.04M | -$111.78M |
| EBITDA | -$172.03M | -$113.14M |
| EPS (basic) | -3.79 | -2.83 |
| EPS (diluted) | -3.79 | -2.83 |
| Weighted avg. shares (diluted) | 46.76M | 39.45M |
| Balance sheet | ||
| Cash & equivalents | $165.70M | $22.52M |
| Short-term investments | $275.79M | $212.59M |
| Current assets | $465.66M | $244.57M |
| PP&E, net | $499,000 | $336,000 |
| Total assets | $466.56M | $245.12M |
| Current liabilities | $44.15M | $31.72M |
| Long-term debt | $137.55M | $105.09M |
| Total debt | $137.55M | $105.09M |
| Total liabilities | $366.00M | $129.50M |
| Shareholders' equity | $100.56M | $115.62M |
| Net debt | -$28.16M | $82.58M |
| Shares outstanding | 48.24M | 37.14M |
| Cash flow statement | ||
| Operating cash flow | -$153.28M | -$83.47M |
| Capital expenditure | $249,000 | $250,000 |
| Free cash flow | -$153.53M | -$83.72M |
| Investing cash flow | -$64.08M | -$63.07M |
| Financing cash flow | $360.55M | $138.39M |
| Depreciation & amortization | $167,000 | $130,000 |
| Stock-based compensation | $21.38M | $6.99M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.